Publications 2005
Batman E, de Wit R
[Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone]
Ned Tijdschr Geneeskd. 2005 Oct 29;149(44):2442-5
Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C,
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
J Clin Oncol. 2005 Oct 1;23(28):7081-8
Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG
Survival and prognostic factors in BRCA1-associated breast cancer.
Ann Oncol. 2006 Mar;17(3):391-400
Brooimans RA, de Leeuw N, Bontenbal M, Gratama JW
An immunomagnetic epithelial tumor cell enrichment model for minimal residual disease detection of cytokeratin 8+ malignancies.
J Biol Regul Homeost Agents. 2005 Jan-Jun;19(1-2):84-91
Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Cancer Biol Ther. 2005 Nov;4(11):1270-4
Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Cancer Biol Ther. 2005 Jul;4(7):747-52
de Beukelaar JW, van Arkel C, van den Bent MJ, van't Veer MB, van Doornum GJ, Cornelissen JJ, Sillevis Smitt PA, Gratama JW
Resolution of EBV(+) CNS lymphoma with appearance of CSF EBV-specific T cells.
Ann Neurol. 2005 Nov;58(5):788-92
de Jonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
Clin Cancer Res. 2005 May 15;11(10):3806-13
de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH
Role of pharmacogenetics in irinotecan therapy.
Cancer Lett. 2006 Mar 8;234(1):90-106
de Jong FA, Engels FK, Mathijssen RH, van Zuylen L, Verweij J, Peters RP, Sparreboom A
Medicinal cannabis in oncology practice: still a bridge too far?
J Clin Oncol. 2005 May 1;23(13):2886-91
de Wit R
Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
Eur J Cancer. 2005 Mar;41(4):502-7
de Wit R, Aapro M, Blower PR
Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
Cancer Chemother Pharmacol. 2005 Sep;56(3):231-8
Engels FK, Sparreboom A, Mathot RA, Verweij J
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Br J Cancer. 2005 Jul 25;93(2):173-7
Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
J Clin Oncol. 2005 Aug 1;23(22):5188-97
Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6908-15
Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
J Clin Oncol. 2005 Feb 1;23(4):732-40
Klijn JG, de Vries EG
[The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer]
Ned Tijdschr Geneeskd. 2005 Mar 19;149(12):618-22
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Int J Cancer. 2005 Nov 20;117(4):596-604
Lamers CH, Gratama JW, Pouw NM, Langeveld SC, Krimpen BA, Kraan J, Stoter G, Debets R
Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.
Hum Gene Ther. 2005 Dec;16(12):1452-62
Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Cancer Res. 2005 May 15;65(10):4101-17
Mathijssen RH, van Schaik RH
Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
Eur J Cancer. 2006 Jan;42(2):141-8
Planting A, de Jong M, Jansen P, Kerrebijn J, Smith M, Verweij J
Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer.
Eur J Cancer. 2005 Jan;41(1):93-7
Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J
A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42
Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB, Verweij J
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Cancer Chemother Pharmacol. 2005 Jan;55(1):91-9
Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Gratama JW, Stoter G, Huber C, Hack CE
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Cancer Immunol Immunother. 2005 Jan;54(1):37-43
Setyono-Han B, Stürzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Thromb Haemost. 2005 Apr;93(4):779-86
Seynaeve C, Brekelmans CT
Tailoring breast cancer therapy to genetic status.
Lancet. 2005 May 14-20;365(9472):1672-3
Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Clin Cancer Res. 2005 Oct 15;11(20):7311-21
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G
Side effects of interferon-alpha therapy.
Pharm World Sci. 2005 Dec;27(6):423-31
Sleijfer S, Seynaeve C, Verweij J
Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.
Oncologist. 2005 Nov-Dec;10(10):833-41
Sleijfer S, Stoter G
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Nat Clin Pract Oncol. 2005 Feb;2(2):70-1
Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J
The potential of statins as part of anti-cancer treatment.
Eur J Cancer. 2005 Mar;41(4):516-22
Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):703-11
Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clin Cancer Res. 2005 Feb 15;11(4):1504-11
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
J Clin Oncol. 2005 Feb 1;23(4):889-98
ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
J Clin Oncol. 2005 Feb 20;23(6):1070-7
Umar A, Dalebout JC, Timmermans AM, Foekens JA, Luider TM
Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry.
Proteomics. 2005 Jul;5(10):2680-8
van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J
What is the role of dose-dense therapy?
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-40
van Meerten E, van der Gaast A
Systemic treatment for oesophageal cancer.
Eur J Cancer. 2005 Mar;41(5):664-72
Verweij J
Pharmaceutical industry, investigators and institutions: Partners or tools?
Eur J Cancer. 2005 Oct;41(15):2204-5
Verweij J
New targets in oncology drug development.
Clin Adv Hematol Oncol. 2005 Oct;3(10):754-5
Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R
Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Gene Ther. 2005 Jan;12(2):140-6
Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.
J Immunol. 2005 Jun 15;174(12):7853-8